Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;2(5):424-6.
doi: 10.7150/thno.4428. Epub 2012 May 1.

Molecular imaging and radiotherapy: theranostics for personalized patient management

Irina Velikyan  1
Affiliations

Molecular imaging and radiotherapy: theranostics for personalized patient management

Irina Velikyan. Theranostics. 2012.

Abstract

This theme issue presents current achievements in the development of radioactive agents, pre-clinical and clinical molecular imaging, and radiotherapy in the context of theranostics in the field of oncology.

Keywords: PET; Radiotherapy; SPECT; nuclear medicine; receptor; theranostics.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The author has declared that no conflict of interest exists.

References

    1. Sörensen J. How does the patient benefit from clinical PET? Theranostics. 2012;2:427–36. - PMC - PubMed
    1. Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labelled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics. 2012;2:437–47. - PMC - PubMed
    1. Öberg K. Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs) Theranostics. 2012;2:448–58. - PMC - PubMed
    1. Garske U, Sandström M, Johansson S, Granberg D, Lundqvist H, Lubberink M, Sundin A, Eriksson B. Lessons on tumour response: Imaging during therapy with 177Lu-DOTA-octreotate. A case report on a patient with a large volume of a poorly differentiated neuroendocrine tumour. Theranostics. 2012;2:459–71. - PMC - PubMed
    1. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espanan G, Sharif R, MacKenzie S, Kosari K, Barakat O, Naqvi Sh, Seng JE, Anthony L. Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide. Theranostics. 2012;2:472–80. - PMC - PubMed